Literature DB >> 17699833

Serum immunoglobulin G antibodies to the GOR autoepitope are present in patients with occult hepatitis C virus (HCV) infection despite lack of HCV-specific antibodies.

Juan A Quiroga1, Inmaculada Castillo, Javier Bartolomé, Vicente Carreño.   

Abstract

Antibody responses to the GOR autoepitope are frequently detected among anti-hepatitis C virus (anti-HCV)-positive patients with chronic hepatitis. Sera from 110 anti-HCV-negative patients with occult HCV infection, as diagnosed by detection of HCV RNA in hepatic tissue, were investigated for GOR antibody reactivity. A positive test for anti-GOR immunoglobulin G (IgG) was found for 22 (20%) of them. The frequency and titers of anti-GOR IgG were significantly lower than those in chronic hepatitis C patients (70/110, 63.6%; P < 0.001). Anti-GOR IgG was not detected in any of the 120 patients with HCV-unrelated liver disease. The anti-GOR IgG assay showed specificity and sensitivity values of 100% and 20%, respectively, among the sera from patients with occult HCV infection; the positive and negative predictive values were 100% and 44.3%, respectively. None of the clinical, laboratory, or histological characteristics of the patients with occult HCV infection were different according to GOR antibody status, except that the percentage of HCV RNA-positive hepatocytes was significantly greater (P = 0.042) in patients with occult HCV infection who tested positive for anti-GOR IgG. In conclusion, serum anti-GOR IgG is present in patients with occult HCV infection, despite a lack of detectable HCV-specific antibodies as determined by commercial tests. Testing for anti-GOR IgG in patients in whom HCV RNA is not detected in their sera may help with the identification of a subset of patients with occult HCV infection without the need to perform a liver biopsy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699833      PMCID: PMC2168120          DOI: 10.1128/CVI.00128-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  33 in total

1.  Measurement of anti-GOR antibodies in prevention of post-transfusion non-A, non-B hepatitis.

Authors:  H Yoshizawa; N Nojiri; K Takahashi
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

Review 2.  Classification of chronic viral hepatitis: a need for reassessment.

Authors:  P J Scheuer
Journal:  J Hepatol       Date:  1991-11       Impact factor: 25.083

3.  An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen.

Authors:  S Mishiro; K Takeda; Y Hoshi; A Yoshikawa; T Gotanda; Y Itoh
Journal:  Autoimmunity       Date:  1991       Impact factor: 2.815

4.  Comparative study between occult hepatitis C virus infection and chronic hepatitis C.

Authors:  M Pardo; J M López-Alcorocho; E Rodríguez-Iñigo; I Castillo; V Carreño
Journal:  J Viral Hepat       Date:  2007-01       Impact factor: 3.728

5.  The GOR gene product cannot cross-react with hepatitis C virus in humans.

Authors:  R Koike; T Iizuka; T Watanabe; N Miyasaka
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

6.  Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process.

Authors:  S Mishiro; Y Hoshi; K Takeda; A Yoshikawa; T Gotanda; K Takahashi; Y Akahane; H Yoshizawa; H Okamoto; F Tsuda
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

7.  Significance of antibody to the host cellular gene derived epitope GOR in chronic hepatitis C virus infection.

Authors:  J Y Lau; G L Davis; E Orito; K P Qian; M Mizokami
Journal:  J Hepatol       Date:  1993-02       Impact factor: 25.083

8.  Immune response to GOR, a marker for non-A, non-B hepatitis and its correlation with hepatitis C virus infection.

Authors:  S U Mehta; S Mishiro; K Sekiguchi; T Leung; G J Dawson; L M Pendy; D A Peterson; S G Devare
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

9.  Anti-GOR and hepatitis C virus in autoimmune liver diseases.

Authors:  G Michel; A Ritter; G Gerken; K H Meyer zum Büschenfelde; R Decker; M P Manns
Journal:  Lancet       Date:  1992-02-01       Impact factor: 79.321

10.  Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown.

Authors:  Inmaculada Castillo; Margarita Pardo; Javier Bartolomé; Nuria Ortiz-Movilla; Elena Rodríguez-Iñigo; Susana de Lucas; Clara Salas; Jose A Jiménez-Heffernan; Arturo Pérez-Mota; Javier Graus; Juan Manuel López-Alcorocho; Vicente Carreño
Journal:  J Infect Dis       Date:  2003-12-31       Impact factor: 5.226

View more
  4 in total

1.  Hepatitis C virus, human immunodeficiency virus and Pseudomonas phage PS5 triad share epitopes of immunogenic determinants.

Authors:  Zhabiz Golkar; Nusrat Jamil
Journal:  Virol J       Date:  2010-11-26       Impact factor: 4.099

Review 2.  Occult HCV Infection: The Current State of Knowledge.

Authors:  Mohammad Saeid Rezaee-Zavareh; Reza Hadi; Hamidreza Karimi-Sari; Mohammad Hossein Khosravi; Reza Ajudani; Fardin Dolatimehr; Mahdi Ramezani-Binabaj; Seyyed Mohammad Miri; Seyed Moayed Alavian
Journal:  Iran Red Crescent Med J       Date:  2015-11-29       Impact factor: 0.611

3.  Expansion of a 12-kb VNTR containing the REXO1L1 gene cluster underlies the microscopically visible euchromatic variant of 8q21.2.

Authors:  Christine Tyson; Andrew J Sharp; Monica Hrynchak; Siu L Yong; Edward J Hollox; Peter Warburton; John Ck Barber
Journal:  Eur J Hum Genet       Date:  2013-09-18       Impact factor: 4.246

4.  Digital genotyping of macrosatellites and multicopy genes reveals novel biological functions associated with copy number variation of large tandem repeats.

Authors:  Manisha Brahmachary; Audrey Guilmatre; Javier Quilez; Dan Hasson; Christelle Borel; Peter Warburton; Andrew J Sharp
Journal:  PLoS Genet       Date:  2014-06-19       Impact factor: 5.917

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.